MORPHOLOGY AND CELL IMAGING CORE

形态学和细胞成像核心

• 批准号: 7767528
• 负责人: CATIA STERNINI
• 金额: $ 12.17万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2014-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7767528
• 关键词: 3-Dimensional; Antibodies; Arts; Biosensor; Calcium; Cell physiology; Cells; Cellular biology; Charge; Collaborations; Communities; Computer software; Disease; Effectiveness; Electrophysiology (science); Ensure; Equipment; Functional Imaging; Funding; Goals; Hormonal; Housing; Human Resources; Image; Image Analysis; Imaging Techniques; Imaging technology; Institutes; Investigation; Label; Laboratories; Lasers; Leadership; Life; Maintenance; Medicine; Methodology; Microscope; Monoclonal Antibodies; Morphology; Mus; Nanotechnology; Neurobiology; Neurons; Pathogenesis; Pathologist; Pathology; Pathway interactions; Play; Proteins; Publications; Quantum Dots; Reagent; Research; Research Institute; Research Personnel; Research Project Grants; Resource Sharing; Resources; Role; Second Messenger Systems; Services; Signal Pathway; Signal Transduction; Signaling Molecule; System; Technical Expertise; Technology; Tissues; Training; Update; brain research; cell type; cellular imaging; experience; gastrointestinal; improved; instrumentation; interest; macromolecule; medical schools; member; patch clamp; programs; receptor; response; second messenger

The Morphology and Cell Imaging Core has been providing expertise, technical support and assistance for morphological and imaging approaches as well as state-of-the-art equipment for sophisticated imaging techniques to the DDRCC members for over 18 years under the leadership of Dr. Sternini. The services provided by the core have been instrumental for studies that have elucidated the tissue and cellular distribution of signaling molecules that play a role in the control of gastrointestinal (Gl) function and in the pathogenesis of Gl disorders as well as for visualizing signaling pathways that regulate cellular functions. The studies that have benefited from the core have made important advances in our understanding of functional interactions between neuronal and hormonal pathways regulating Gl functions and have resulted in many publications and in long-lasting collaborations. There have been several additions and updates in services throughout the years to reflect the needs of DDRCC members and the evolving of morphological and imaging technologies, with the goal of enhancing the Core capabilities. Enhancement of morphological capabilities includes 1) the addition of mouse pathology services and 2) the incorporation of a Central Bank of well characterized antibodies. The mouse pathology services have been added in our previous competitive renewal in response to the increasing need of many CURE: DDRCC investigators for expertise and assistance in defining phenotypical abnormalities or pathologies that can be detected in genetically manipulated mice, which are increasingly used at CURE:DDRCC. Dr. Nora Rozengurt, an experienced veterinary pathologist with extensive expertise in natural and experimentally induced mouse pathology has been serving as Core Associate Director to supervise this service, which has been extensively used during the past funded cycle. The antibodies central bank has been added to provide a centralized system for the wealth of antibodies that have been produced at CURE during previous funding periods and for other antibodies that are used by many investigators as markers for specific cell types or intracellular signaling molecules. The availability of a centralized bank of well characterized and validated antibodies of interest to CURE: DDRCC investigators is a powerful resource that will allow an effective access of CURE:DDRCC investigators to a variety of reagents that can be utilized through the Morphology and Cell Imaging Core. Dr. Gordon Ohning will join the Core as Associate Director to be in charge of the maintenance of the Central Bank of antibodies. There has been a significant enhancement of the capabilities of our imaging services, including 1) the addition of highly sophisticated equipment and 2) the incorporation of new imaging technologies that will further advance our ability to visualize molecules at the cellular and subcellular levels and changes in second messenger systems following cellular activation. A major enrichment of our imaging facilities has been the addition of a state-of-the-art confocal microscope, a Zeiss LSM 510 Meta equipped with sophisticated software (e.g. deconvolution, image analysis, 3-D rendering) for live and fixed cell imaging. This system was acquired with the help of institutional funds from the David Geffen UCLA School of Medicine just prior to the previous competitive renewal, and since then it has been used heavily by an increasing number of CURE: DDRCC investigators. During the past funded cycle, we have also enhanced our instrumentation for calcium imaging by acquiring a Zeiss Pascal confocal microscope equipped with both short (405 nm) and visible wavelength lasers for excitation. A whole cell patch clamp recording setup is available to perform single cell electrophysiology simultaneously with confocal live cell imaging. This microscope, which has also been acquired with the help of institutional funds from the School of Medicine Dean's office, is housed at UCLA in the same building as the Zeiss 510 Meta confocal and has been extensively used by severa DDRCC investigators. Our services have also been upgraded by the addition of new imaging technologies in live cells, including quantum dots (Q-dots), photoactivatable proteins and second messengers' biosensors labeled with fluorescent tags. These significant improvements will further advance our ability to visualize macromolecules at the cellular and subcellular levels and changes in second messenger systems following cellular activation. Dr. Osvaldo Rey will join the Core personnel as Core Co-Director to supervise the new imaging methodologies that are proposed to cover the new needs of many DDRCC investigators. Finally, there will be an increased use of shared resources that are available for CURE: DDRCC investigators through arrangements made by the Core Director and existing Cores at UCLA, which are supported by the Department of Pathology and Laboratory Medicine, the Brain Research Institute and the Nanotechnology Institute. These interactions will continue to be a major effort of the Morphology and Cell Imaging Core to enhance the technical capabilities of the Core and ensure optimal utilization of shared resources within the UCLA community that includes the CURE: DDRCC community. Overall, the addition of services briefly outlined above and explained in more detail later in the body of the application reflects the evolving of the DDRCC research interests and focus, and the advances in morphological and imaging technologies. These additions will provide state-of-the-art approaches and equipment to many CURE: DDRCC investigators who are interested in elucidating fundamental normal or abnormal mechanisms in different types of cells controlling digestive functions.

形态和细胞成像核心一直在提供专业知识，技术支持和 为形态学和成像方法的帮助以及最先进的设备 在博士的领导下，向DDRCC成员提供了18年以上的复杂成像技术 斯特尼尼。核心提供的服务对阐明的研究起了重要作用 信号分子的组织和细胞分布在胃肠道控制中起作用 （GL）功能和GL疾病的发病机理，以及可视化信号通路 调节细胞功能。从核心中受益的研究变得重要 我们对神经元和激素途径之间功能相互作用的理解的进步 调节GL功能，并导致许多出版物和长期合作。 多年来，服务上有几种补充和更新，以反映需求 DDRCC成员以及形态和成像技术的发展，目的是 增强核心功能。形态学能力的增强包括1） 添加鼠标病理学服务和2）井中银行的合并 特征抗体。鼠标病理服务已在我们以前的竞争中添加 为了响应许多治疗需求的恢复：DDRCC调查人员的专业知识和 可以在遗传学上检测到的表型异常或病理的帮助 操纵小鼠，越来越多地用于治疗：DDRCC。 Nora Rozengurt博士，经验丰富 兽医病理学家具有自然和实验诱导的小鼠病理方面的广泛专业知识 一直担任监督该服务的核心副主任，该服务已被广泛使用 在过去的资助周期中。添加了抗体中央银行以提供集中式 以前的融资期在治愈期间生产的大量抗体的系统 以及许多研究人员用作特定细胞类型或 细胞内信号分子。一家良好特征的集中式银行的可用性和 经过验证的治愈抗体：DDRCC调查人员是一种强大的资源，将允许 有效访问治愈方法：DDRCC调查人员可以通过可以通过 形态和细胞成像核心。戈登·奥宁（Gordon Ohning）博士将加入核心董事的核心 维持抗体的维护费用。 我们的成像服务能力有很大的增强，包括1） 添加高度复杂的设备和2）合并新成像技术 将进一步提高我们在细胞和亚细胞水平上可视化分子的能力，并改变 在细胞激活之后的第二个允许系统中。我们的成像的主要丰富 设施一直是最先进的共聚焦显微镜，一个Zeiss LSM 510 meta 配备了复杂的软件（例如反卷积，图像分析，3-D渲染） 活细胞成像和固定细胞成像。该系统是在从机构资金的帮助下获取的 大卫·盖芬·加州大学（David Geffen UCLA）医学院就在上一次竞争性续约之前 越来越多的治疗方法大量使用：DDRCC研究人员。在过去 资助的周期，我们还通过获得Zeiss增强了钙成像的仪器 配备短​​（405 nm）和可见波长激光器的Pascal共聚焦显微镜 励磁。全单元格夹夹记录设置可用于执行单个单元格 与共聚焦活细胞成像同时进行电生理学。这个显微镜，也有 在医学院院长办公室的机构资金的帮助下，被安置在 UCLA与Zeiss 510 Meta共共焦点同一建筑物，已被Severa广泛使用 DDRCC调查人员。我们的服务也通过添加新成像升级 活细胞中的技术，包括量子点（Q点），可光活化蛋白和 第二使者的生物传感器标有荧光标签。这些重大改进将 进一步提高了我们在细胞和亚细胞水平上可视化大分子的能力以及 细胞激活后第二信使系统的变化。 Osvaldo Rey博士将加入核心 人员作为核心联合指导，以监督提议覆盖的新成像方法 许多DDRCC调查人员的新需求。 最后，将越来越多地使用共享资源来治疗：DDRCC 调查人员通过核心董事和UCLA现有核心的安排， 由病理学和实验室医学系，大脑研究所和 纳米技术研究所。这些互动将继续是形态学和 细胞成像核心以增强核心的技术能力并确保最佳利用 UCLA社区中的共享资源包括CURE：DDRCC社区。 总体而言，添加上面简要概述的服务并在身体后面更详细地进行了解释 申请的内容反映了DDRCC研究兴趣和重点的发展，以及进步 形态学和成像技术。这些增加将提供最新的方法，并 许多治愈的设备：有兴趣阐明基本正常的DDRCC调查人员 或控制消化功能的不同类型的细胞中的异常机制。